CEO Joseph Burnett stated that ClearPoint Neuro ended 2025 on its strongest financial quarter of the year, highlighting "a newly acquired and commercialized neurocritical care product line and genuine ...
ClearPoint Health (“ClearPoint”) is a medical stop-loss captive platform for small and mid-sized employers. ClearPoint’s platform empowers employers and benefit advisors to transition employee health ...
[Audio Gap] comments made on this call may include statements that are forward-looking within the meaning of securities laws. These forward-looking statements may include, without limitation, ...
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--May 19, 2008--Alliant Insurance Services, one of the nation’s largest specialty insurance brokerage firms, has announced the acquisition of Seattle, Wash.-based ...
Combined clearance of the navigation and drug delivery technologies enables Canadian neurosurgery centers to leverage the Company's flagship image-guidance workflow and advances ClearPoint Neuro's ...
William Wood, an analyst from B.Riley Financial, reiterated the Buy rating on ClearPoint Neuro (CLPT – Research Report). The associated price target is $10.00. William Wood’s rating is based on ...
Announcement is made after successful proof-of-concept trial in a preclinical model of intravenous delivery of large molecule tracers across the blood-brain barrier guided by prototype systems, ...
SOLANA BEACH, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results